Specialty / Expertise

Solid Tumor

Research Interests

Phase I

Current Research Projects

Training

Dr. Cheever received his MD from University of Michigan, Ann Arbor, MI. He completed his Internal Medicine Residency at the University of Washington, Seattle, WA. He was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, WA.

Selected Publications:

Mossman SP, Evans LS, Fang H, Staas J, Tice T, Raychaudhuri S, Grabstein KH, Cheever MA, Johnson ME. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants. Vaccine. 2005 May 20;23(27):3545-54.

Henderson RA, Mossman S, Nairn N, Cheever MA. Cancer vaccines and immunotherapies: emerging perspectives. Vaccine. 2005 Mar 18; 23(17-18):2359-62.

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA.; Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol. 2004 May 15;22(10):1916-25.

Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ.; Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003 Sep 1;171(5):2251-61.